Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the STEEPLE trial

European Heart Journal

Volumn 29, Issue 4, 2008, Pages 462-471

  Montalescot, Gilles ^a   Cohen, Marc ^b   Salette, Genevieve ^c   Desmet, Walter J ^d   Macaya, Carlos ^e   Aylward, Philip E G ^f   Steg, Ph Gabriel ^g   White, Harvey D ^h   Gallo, Richard ⁱ   Steinhubl, Steven R ^j  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^c SANOFI   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Hospital Universitario   (Spain)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g BICHAT HOSPITAL   (France)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j UNIVERSITY OF KENTUCKY   (United States)

more..

Author keywords

Anticoagulation; Enoxaparin; Percutaneous coronary intervention; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; THIENOPYRIDINE DERIVATIVE;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; DEATH; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIA; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; TREATMENT OUTCOME;

EID: 39349094894     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn008     Document Type: Article

References (42)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):188S-203S.
2. Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.
3. Borentain M, Montalescot G, Bouzamondo A, Choussat R, Hulot JS, Lechat P. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter Cardiovasc Interv 2005;65:212-221.
4. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-847.
5. Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T, Dalby M, Choussat R, Cohen A, Slama M, Steg PG, Dubois-Rande JL, Metzger JP, Tarragano F, Guermonprez JL, Drouet L, ARMADA Investigators. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 2003;91:925-930.
6. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-114.
7. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
8. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593- 1601.
9. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A, Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-244.
10. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
11. Collet JP, Montalescot G, Golmard JL, Tanguy ML, Ankri A, Choussat R, Beygui F, Drobinski G, Vignolles N, Thomas D. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Am Heart J 2004;147:655-661.
12. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
13. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-634.
14. Levine GN, Ferrando T. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis 2004;17:167-171.
15. Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, Ozoux ML, Pensyl CE, Bigonzi F. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163-170.
16. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391- 1395.
17. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM, Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003;41:20-25.
18. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M, NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-278.
19. Kereiakes DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, Burkert ML, Aquilina JW, DeLoof M, Broderick TM, Shimshak TM. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-352.
20. Madan M, Radhakrishnan S, Reis M, Paradiso-Hardy FL, Godin-Edgecombe M, Sparling C, Phillips AM, Shanmugasegaram S, Fort S, Naqvi SZ, Cohen EA. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol 2005;95:1295-1301.
21. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol 2000;12(Suppl. E):E14-E18.
22. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-e121.
23. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003;41:386-393.
24. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004;110:994-998.
25. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-398.
26. Chen WH, Lau CP, Lau YK, Ng W, Lee PY, Yu CM, Ma E. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002;14:439-442.
27. Drodz J, Opalinska E, Wojcik J, Madejczyk A. The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina. Kardiol Pol 2001;55:520-524.
28. Dudek D, Dabrowski M, Ochala A, Lesiak M, Wnek A, Bryniarski L, Zmudka K, Zymek P, Dubiel JS, Gil R; on behalf of the Study Group. Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary intervention. (Abstract). Am J Cardiol 2000;86(Suppl. 1): TCT-34(15i).
29. Hussein M, Galeote G, Sobrino N, Sanchez-Recalde A, Calvo L, Yunda H, Sobrino JA. Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: a randomized study. Eur Heart J 2001;22(Suppl.):663.
30. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006- 1017.
31. Bijsterveld NR, Moons AH, Meijers JC, Levi M, Buller HR, Peters RJ. The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. J Am Coll Cardiol 2003;42:424-427.
32. Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol 2005;60:364-373.
33. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
34. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
35. Stone CJ, Koo CY. Additive spline in statistics. Proceedings of the Computing Section of the American Statistical Association. Washington, DC: American Statistical Association; 1985. 45-48.
36. Chen JL, Chen J, Qiao SB, Guo YL, Wu YJ, Dai J, Yuan JQ, Qin XW, Yang YJ, Gao RL. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease. Chin Med J (Engl) 2006;119:355-359.
37. Zalc S, Lemos PA, Esteves A, Ribeiro EE, Horta P, Nicolau JC, Ramires JA, Cohen M, Martinez EE. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin. J Invasive Cardiol 2006;18:45-48.
38. Brieger D, Van der Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G, GRACE Investigators. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2007;153:960-969.
39. Steinhubl S, White H, King S, Gallo R, Montalescot G, for the STEEPLE investigators. Safety and efficacy of glycoprotein IIb/IIIa inhibitors with intravenous enoxaparin in patients undergoing elective percutaneous coronary intervention: findings from the STEEPLE trial. J Am Coll Cardiol 2006;47:B45.
40. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-966.
41. Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, Collet J-P, Steinhubl SR, Montalescot G. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med 2007;167:2423-2430.
42. Cohen M, Steinhubl SR, White HD, Gallo R, Montalescot G, for the STEEPLE Investigators. Use of glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing elective percutaneous coronary intervention is associated with increased major bleeding: a subanalysis of the STEEPLE trial (abstract). SCAI 2007:D-47.